Expand AZN Menu
AZN MENU

AZN Latest Press Releases

-- November 12, 2024 --

AstraZeneca's 9M and Q3 2024 results Business Wire 7:00 AM
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States Business Wire 7:00 AM

-- November 10, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN PRNewswire 12:00 PM

-- November 8, 2024 --

ENHERTU Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product Business Wire 8:00 AM
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps Business Wire 7:00 AM

-- November 7, 2024 --

AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 Business Wire 7:00 AM

-- October 30, 2024 --

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Business Wire 8:00 AM

-- October 7, 2024 --

AIRSUPRA (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial Business Wire 7:00 AM

-- October 3, 2024 --

CALQUENCE (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma Business Wire 7:00 AM

-- October 2, 2024 --

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma Business Wire 4:05 PM

-- October 1, 2024 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy Business Wire 7:00 AM
ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy Business Wire 2:00 AM

-- September 26, 2024 --

TAGRISSO (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer Business Wire 7:00 AM

-- September 23, 2024 --

Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Business Wire 7:00 AM
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial Business Wire 2:00 AM

-- September 20, 2024 --

FLUMIST approved for self-administration in the US Business Wire 4:34 PM

-- September 18, 2024 --

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis Business Wire 7:00 AM

-- September 17, 2024 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 Globe Newswire 11:23 AM

-- September 16, 2024 --

IMFINZI (durvalumab) plus IMJUDO (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial Business Wire 7:00 AM

-- September 15, 2024 --

IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial Business Wire 10:30 AM

-- September 13, 2024 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases Business Wire 10:00 AM
ENHERTU Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases Business Wire 10:00 AM

-- September 10, 2024 --

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives Yolowire 6:58 PM
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing PRNewswire 10:16 AM

-- September 9, 2024 --

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial Business Wire 1:50 PM
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial Business Wire 1:50 PM
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 Business Wire 1:00 AM

-- September 8, 2024 --

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial Business Wire 12:25 PM
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial Business Wire 12:25 PM

-- September 3, 2024 --

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 Business Wire 7:00 AM

-- August 19, 2024 --

ENHERTU Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Business Wire 2:00 AM

-- August 16, 2024 --

IMFINZI (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery Business Wire 7:00 AM

-- August 15, 2024 --

IMFINZI (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US Business Wire 7:00 AM

-- August 6, 2024 --

Cellectis Provides Financial Results for the Second Quarter 2024 Globe Newswire 4:30 PM

-- July 29, 2024 --

Fixed-duration CALQUENCE (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial Business Wire 7:00 AM

-- July 25, 2024 --

AstraZeneca's H1 and Q2 2024 Financial Results Business Wire 7:00 AM

-- July 23, 2024 --

Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca PRNewswire 11:17 AM

-- June 25, 2024 --

IMFINZI (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial Business Wire 7:00 AM

-- June 20, 2024 --

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth Globe Newswire 10:00 AM

-- June 17, 2024 --

IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Business Wire 7:00 AM

-- June 16, 2024 --

CALQUENCE (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Business Wire 7:00 AM

-- June 12, 2024 --

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes Business Wire 5:35 PM